An announcement was issued on September 4, stating that the company plans to purchase 100% of the equity of Pengli Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Pengli Biotechnology" or "the target company") through the issuance of shares and payment of cash, and to issue shares to no more than 35 specific investors to raise matching funds.

The company previously received an audit inquiry letter from the Shanghai Stock Exchange and has completed its response to the relevant questions. The company's independent financial advisor, accounting firm, law firm, and appraisal agency have reviewed the relevant matters in the audit inquiry letter and issued clear opinions. They have also revised the relevant documents and materials previously released by the company. The company has reviewed and self-examined the entire text of the "Restructuring Report" (revised draft), and has made minor additions to the text, which have no impact on the transaction plan.

On September 2nd, the company held the 13th meeting of its second board of directors and the 12th meeting of its second board of supervisors, reviewing and approving the relevant adjustment plan proposal, which adjusted the total amount of matching funds raised from no more than 730 million yuan to no more than 362.0499 million yuan. The company stated that this transaction plan adjustment is to reduce the amount of matching funds raised and does not involve any changes to the underlying assets or the counterparty, nor does it involve the addition or increase of matching funds raised. According to relevant documents, this transaction plan adjustment does not constitute a major adjustment.

https://finance.eastmoney.com/a/202509043504567857.html